Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Esophageal Neoplasms
/ drug therapy
Esophagogastric Junction
/ pathology
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Palliative Care
/ methods
Stomach Neoplasms
/ drug therapy
Treatment Outcome
HER2
Upper gastrointestinal tract
chemotherapy
esophageal cancer
gastric cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
22
12
2019
revised:
08
01
2020
accepted:
09
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
2
2020
Statut:
ppublish
Résumé
A standard treatment recommendation for advanced stage gastroesophageal cancer is still missing. We retrospectively analyzed clinical data of patients with inoperable locally advanced or metastatic gastroesophageal cancer treated between 2001 and 2017 at the Vienna General Hospital, Austria. Administration of systemic therapy was positively associated with overall survival (OS) (469 days vs. 185 days; p<0.001), while palliative gastrectomy or radiotherapy showed no correlation. OS was significantly longer in patients receiving capecitabine/oxaliplatin (XELOX) vs. leucovorin/5-FU/oxaliplatin (FOLFOX) (600 days vs. 327 days, p<0.05). Comparison of doublet vs. triplet chemotherapies showed no difference in OS, but triplet chemotherapy resulted in more adverse events. The anti-HER2-antibody trastuzumab doubled OS (836 days vs. 399 days, p=0.053). Capecitabine may be preferably used over infused 5-FU and doublet chemotherapy over triplet chemotherapy in the first-line palliative setting of advanced gastroesophageal cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
A standard treatment recommendation for advanced stage gastroesophageal cancer is still missing.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed clinical data of patients with inoperable locally advanced or metastatic gastroesophageal cancer treated between 2001 and 2017 at the Vienna General Hospital, Austria.
RESULTS
RESULTS
Administration of systemic therapy was positively associated with overall survival (OS) (469 days vs. 185 days; p<0.001), while palliative gastrectomy or radiotherapy showed no correlation. OS was significantly longer in patients receiving capecitabine/oxaliplatin (XELOX) vs. leucovorin/5-FU/oxaliplatin (FOLFOX) (600 days vs. 327 days, p<0.05). Comparison of doublet vs. triplet chemotherapies showed no difference in OS, but triplet chemotherapy resulted in more adverse events. The anti-HER2-antibody trastuzumab doubled OS (836 days vs. 399 days, p=0.053).
CONCLUSION
CONCLUSIONS
Capecitabine may be preferably used over infused 5-FU and doublet chemotherapy over triplet chemotherapy in the first-line palliative setting of advanced gastroesophageal cancer.
Identifiants
pubmed: 32014941
pii: 40/2/965
doi: 10.21873/anticanres.14030
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-975Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.